Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3726 Comments
1804 Likes
1
Varner
Influential Reader
2 hours ago
There’s got to be more of us here.
👍 247
Reply
2
Namoni
Legendary User
5 hours ago
Anyone else thinking this is bigger than it looks?
👍 169
Reply
3
Greenwood
Engaged Reader
1 day ago
I feel like I need to discuss this with someone.
👍 243
Reply
4
Reinald
Experienced Member
1 day ago
This made me smile from ear to ear. 😄
👍 222
Reply
5
Sevana
Power User
2 days ago
I was so close to doing it differently.
👍 242
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.